IGF1R and neoplasm: An in-vitro study reported that GSK1838705A, a potent insulin-like growth factor-1 receptor (IGF1R)/IR inhibitor, is capable of decreasing docetaxel-resistant PCa cell viability and migration, as well as in-vivo tumor growth.